| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5304 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2768 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1663 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1333 | 2021 |
| ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques N Van Doremalen, T Lambe, A Spencer, S Belij-Rammerstorfer, ... Nature 586 (7830), 578-582, 2020 | 1139 | 2020 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1129 | 2021 |
| Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 747 | 2021 |
| Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 657 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 588 | 2021 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 487 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 334 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 270 | 2021 |
| Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 SP Graham, RK McLean, AJ Spencer, S Belij-Rammerstorfer, D Wright, ... NPJ vaccines 5 (1), 69, 2020 | 149 | 2020 |
| Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine Y Watanabe, L Mendonça, ER Allen, A Howe, M Lee, JD Allen, H Chawla, ... ACS central science 7 (4), 594-602, 2021 | 134 | 2021 |
| The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world HR Sharpe, C Gilbride, E Allen, S Belij‐Rammerstorfer, C Bissett, K Ewer, ... Immunology 160 (3), 223-232, 2020 | 132 | 2020 |
| Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice AJ Spencer, PF McKay, S Belij-Rammerstorfer, M Ulaszewska, CD Bissett, ... Nature communications 12 (1), 2893, 2021 | 126 | 2021 |
| A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice A Silva-Cayetano, WS Foster, S Innocentin, S Belij-Rammerstorfer, ... Med 2 (3), 243-262. e8, 2021 | 88 | 2021 |
| Intestinal helminths infection of rats (Ratus norvegicus) in the Belgrade area (Serbia): the effect of sex, age and habitat M Kataranovski, I Mirkov, S Belij, A Popov, Z Petrović, Z Gačić, ... Parasite: journal de la Société Française de Parasitologie 18 (2), 189, 2011 | 82 | 2011 |
| Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial M Madhavan, AJ Ritchie, J Aboagye, D Jenkin, S Provstgaad-Morys, ... EBioMedicine 85, 2022 | 75 | 2022 |
| Oxford COVID Vaccine Trial Group Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised … PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... Lancet 396 (10249), 467-478, 2020 | 68 | 2020 |
